Drug major Lupin has launched a generic version of Japan-headquartered Eisai Inc’s Aciphex delayed-release tablets, used to treat gastroesophageal reflux disease, in the US market.
The company’s US-based subsidiary Lupin Pharmaceuticals Inc has launched its generic Rabeprazole Sodium delayed-release tablets, 20 mg in the American market, after having received approval from the US Food and Drug Administration to market it, according to a statement by Lupin.
Lupin’s product is generic equivalent of Eisai Inc’s Aciphex delayed-release tablets, 20 mg, and it is indicated for the treatment of gastroesophageal reflux disease (GERD), it added.
According to IMS MAT June 2013 sales data, Aciphex delayed-release tablets, 20 mg, had annual US sales of around $864.3 million.
Shares of Lupin were trading at Rs 886.30 a piece on the BSE in the late afternoon trade, up 0.3 per cent from their previous close.